[131I]I-131-PD-L1

Also written as I-131-PD-L1

Radionuclide: I-131 t½ 11549 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 1

Breast cancer Head and neck cancer Apoptosis and early treatment response Receptor expression phenotyping Other radioligand therapy

What it is

Compound class: Anti-PD-L1 monoclonal antibody
Target / mechanism: Programmed death-ligand 1 (PD-L1) PMID 29923634
Clinical application: Triple-negative breast cancer PMID 29923634
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	—	80% ± 3%	97% ± 1%	PD-L1 mAb	29923634 2018 J Labelled Comp Radiopharm

Need this precursor?We can point you to suppliers for [131I]I-131-PD-L1, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 29923634: 'Anti-PD-L1 mAb was radiolabeled with iodine-131'.